Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy

Kidney International

Volumn 56, Issue 2, 1999, Pages 650-658

  Yokoyama, Hiroki ^a,b,c   Sato, Ken ^a,b   Okudaira, Maki ^a,b   Morita, Chihiro ^a,b   Takahashi, Chieko ^a,b   Suzuki, Daisuke ^a,b   Sakai, Hideto ^a,b   Iwamoto, Yasuhiko ^a,b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NONE   (Japan)

Author keywords

Charge barrier; Diabetes; Extracellular matrix; Glomerular basement membrane; Sulfation

Indexed keywords

HEPARAN SULFATE;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERMEABILITY BARRIER; PRIORITY JOURNAL; SULFATION; SURFACE CHARGE; URINARY EXCRETION; URINE LEVEL;

EID: 0032775696     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00591.x     Document Type: Article

References (43)

1. 1. MORGENSEN CE, CHACHATI A, CHRISTENSEN CK, CLOSE CF, DECKERT T, HOMMEL E, KASTRUP J, MATHIESEN ER, FELDT-RASMUSSEN B, SCHMITZ A, VIBERTI GC: Microalbuminuria: An early marker of renal involvement in diabetes. Urenia Invest 9:85-05, 1985
2. 2. FELDI-RASMUSSEM B: Microalbuminuria and clinical nephropathy in type 1 (insulin-dependent) diabetes mellilus: Pathophysiological mechanisms and intervention studies. Dan Med Bull 36:405-415, 1989
3. 3. YOKOYAMA H, DECKERT T: Central role of TGF-β in the pathogenesis of diabetic nephropathy and macrovascular complications: A hypothesis. Diabet Med 13:313-320, 1996
4. 4. ZATS R, MEYER TW, RENNKE HG, BRENNER BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic nephropathy. Proc Natl Acad Sci USA 82:5963-5967, 1985
5. 5. DECKERT T, KOFOED-ENEVOLDSEN A, VIDAL P, NORGAARD K. ANDREASEN HB, FELDT-RASMUSSEN B: Size and charge selectivity of glomerular filtration in type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 36:244-251, 1993
6. 6. NAKAMUKA Y, MYERS BD: Charge selectivity of proteinuria in diabetic glomerulopathy. Diabetes 37:1202-1211, 1988
7. 7. VAN DEN BORN J, VAN DEN HFUVEL LPWJ, BAKKER MAH, VEERKAMP JH, ASSMANN KJM, BERDEN JHM: A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 41:115-123, 1992
8. 8. ROSENWEIG LJ, KANWAR YS: Removal of sulfated (heparan sulfate) or non sulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to DI albumin. Lab Invest 47:177-184, 1982
9. 9. VERNIER RL, STEFEES MW, SISSONS-ROSS S, MAUER M: Heparan sulfate proteoglycan in the glomerular basement membrane in type I diabetes mellitus. Kidney Int 41:1070-1080, 1992
10. 10. LINDAHL U, FEINGLOD DS, RODLN L: Biosynthesis of heparin. Trends Biochem Sci 11:221-225, 1986
11. 11. KUSCHE M, LINDAHL U: Biosynthesis of heparin, O-sulfation of D-glucuronic acid units. J Biol Chem 265:15403-15409, 1990
12. 12. KANWAR YS, LIU ZZ, KASHIHARA N, WALLNER EI: Current status of the structural and functional basis of glomerular filtration and proteinuria. Semin Nephrol 11:390-413, 1991
13. 13. COTRAN RS, RENNKE HG: Anionic sites and the mechanisms of proteinuria. N Engl J Med 309:1050-1052, 1983
14. 14. FAROUHAR MG: The glomerular basement membrane: A selective macromolecular filter, in Cell Biology of Extracellular Matrix, edited by HAY ED, New York, Plenum Press, 1991. pp 365-418
15. 15. GALLAGHER JT, WALKER A: Molar distinctions between heparan sulfate and heparin: Analysis of sulfation patterns indicates that heparan sulfate and heparin are separate families of N-sulfated polysaccharides. Biochem J 230:665-674, 1985
16. 16. KJELLIN L, LINDAHL U: Proteoglycans: Structures and interactions. Annu Rev Biochem 60:443-475, 1991
17. 17. LINDAHL U, LIDHOPI K, SPILLMANN D, KIELLEN L: More to heparin than anticoagulation. Thromb Res 75:1-32, 1994
18. 18. KIELLEN L, BIELEFELD D, HOOK M: Reduced sulfation of liver heparan sulfate in experimental diabetic rats. Diabetes 32:337-342, 1983
19. 19. ORELLANA A, HIRSCHBERG CB, WFI Z, SWIEDLER SJ, ISHIHARA M: Molecular cloning and expression of a glycosaminoglycan N-acetylglucosaminyl N-deacetylase from a heparin-producing cell line. J Biol Chem 269:2270-2276, 1904
20. 20. UNGER E, PETTERSSON I, ERRIKSSON UJ, LINDAHL U, KIELLEN L: Decreased activity of the heparan sulfate-modifying enzyme glucosaminyl N-deacetylase in haptocytes from streptozotocin-diabetic rats. J Biol Chem 226:8671-8674, 1991
21. 21. KOFOED-ENEVOLDSEN A, NOONAN D, DECKERI T: Diabetes mellitus induced inhibition of glucosaminyl N-deacetylase: Effect of short-term blood glucose control in diabetic rats. Diabetologia 36:310-315, 1993
22. 22. KOFOED-ENEVOLDSEN A, ERRIKSSON UJ: Inhibition of N-acetylheparosan deacetylase in diabetic rats. Diabetes 40:1449-1452, 1991
23. 23. KOFOED-ENEVOLDSEN A: Inhibition of glucosaminyl N-deacetylase in diabetic rats. Kidney Int 41:763-767, 1992
24. 24. KOFOED-ENEVOLDSEN A, PETERSEN JS, DECKERT: Glucosaminyl N-deacetylase in cultured fibroblasts: Composition of patients with and without diabetic nephropathy, and identification of a possible mechanism for diabetes-induced N-deacetylase inhibition Diabetologia 36:536-540, 1993
25. 25. HARRIS MI: Classification and diagnostic criteria for diabetes mellitus and other categories of glucose tolerance. Print Care 14:628-638, 1988
26. 26. NOMURA T, ODAGIRI R, DEMURA R, AKASHI H, DEMURA H: Evaluation of a new radioimmunoassay kit for urinary albumin. J Med Pharm Sci 22:213-220, 1989
27. 27. DAVID G, BAI XM, VAN DER SCHUEREN B, CASSIMAN JJ, VAN DEN BERGHE H: Developmental changes in heparan sulfate expression: In situ detection with mAbs. J Cell Biol 119:961-975, 1992
28. 28. YANG B, YANG BL, GOETINCK PF: Biotinylated hyaluronic acid as a probe for identifying hyaluronic acid-binding proteins. Anal Biochem 228:299-306, 1995
29. 29. LUBEC G, LEGENSIEIN E, POLLAK A, MEZSIK E: Glomerular basement membrane changes, HbAlc, and urinary excretion of acid glycosaminoglycans in children with diabetes mellitus. Clin Chim Acta 103:45-49, 1980
30. 30. RONAVITA N, REFD P, DONNFLLY PV, HILL L, DIFERRANTE N: The urinary excretion of heparan sulfate by juvenile-and adult-onset diabetic patients. Connect Tissue Res 13:63-67, 1984
31. 31. KlRCHER S, LUBEC G: Urinary excretion of acid glycosaminoglycans and its relationship to proteinuria. Nephron 42:275-276, 1986
32. 32. BAGGIO B, RRIANI G, CICERELLO E, GAMBARO G, BRUTTOMESSO D, TIENGO A, BORSATTI A, CHEPALDI G: Urinary glycosaminoglycans, sialic acid, and lysosomal enzymes increase in nonalbuminuric diabetic patients. Nephron 43:187-190, 1986
33. 33. BAGGIO B, BRIANI G, CICERFLLO E, GAMBARO G, BORSATTI A, CREPALDI G: Urinary glycosaminoglycan excretion and microalbuminuria in diabetes. JAMA 255:3250-3251, 1986
34. 34. BERNARD AM, OULED A, ROFLS H, LAUWERYS R, VANDELEENE B, LAMBERT A: Lack of relationship between urinary glycosaminoglycans and indices of tubular renal damage: Urinary GAGs are an unreliable nephrotoxicity index. Nephron 48:82-83, 1988
35. 35. GAMBARO G, CICERELO E, MASTROSIMONE S, LAVAGNINI T, BAGGIO B: High urinary excretion of urinary excretion of glycosaminoglycans: A possible marker of glomerular involvement in diabetes. Metabolism 38:419-420, 1989
36. 36. REDDI AS: Glomerular and urinary glycosaminoglycans in diabetic rats. Clin Chim Acta 189:211-220, 1990
37. 37. MCAULIFFE AV, FISHER EJ, MCLENNAN SV, YUE DK, TURTLE JR: Urinary glycosaminoglycan excretion in NIDDM subjects: Its relationship to albuminuria. Diabet Med 13:758-763, 1996
38. 38. HAYASHI Y, MAKINO H, OTA Z: Serum and urinary concentrations of type IV collagen and laminin as a marker of microangiopathy in diabetes. Diabet Med 9:366-370, 1992
39. 39. BIENKOWSKI MJ, CONRAD HE: Structural characterization of the oligosaccharides formed by depolymerization of heparin with nitrous acid. J Biol Chem 260:356-365, 1985
40. 40. FUKUTO JM: Chemistry of nitric oxide: Biologically relevant aspects. Adv Pharmacol 34:1-15, 1995
41. 41. VILAR RE, GHAEL D, LI M, BHAGAI DD, ARRIGO LM, COWMAN MK, DWECK HS, ROSENFELD L: Nitric oxide degradation of heparin and heparan sulfate. Biochem J 324:473-479, 1997
42. 42. BANK N, AYNEDJIAN HS: Role of EDRF (nitric oxide) in diabetic hyperfiltration. Kidney Int 43:1306-1312, 1993
43. 43. PFEILSCHIFTER J: Does nitric oxide, an inflammatory mediator of glomerular mesangial cells, have a role in diabetic nephropathy? Kidney Int 48(Suppl 51):S50-S60, 1995